Cell Gene Therapy 101: How Two Sciences Became One in 2026
Introduction: Why “Cell Gene Therapy” Is Really Two Fields in One
Cell therapy and gene therapy did not begin as a single discipline. Each emerged with its own scientific goals, definitions, delivery tools, and approval pathways. Researchers in one camp focused on living cells as medicine; researchers in the other focused on genetic material as medicine.
Today, the phrase “cell gene therapy” is widely used as shorthand for the point where these two sciences meet. That meeting point has accelerated dramatically by 2026, to the extent that many of the most important new treatments cannot be accurately described without referencing both fields at once.
This explainer walks through that convergence in plain language. It covers:
- How ex vivo gene editing of a patient’s own cells fused the two disciplines
- Why the same therapy can be classified differently in the United States and the European Union
- The most current 2026 approval data, including Otarmeni, Tregzi, and the BCL11A-editing mechanism behind Casgevy
- The real-world challenges of manufacturing and access that still shape the field
No prior technical background is assumed. The article is written for general readers, patients and caregivers researching options, and professionals who want a foundational primer before diving into more specialized material.
Two Separate Sciences: Defining Cell Therapy and Gene Therapy
Before discussing how the two fields merged, it helps to understand why they were separated in the first place. They started as different regulatory categories with different therapeutic aims.
What Is Cell Therapy?
Cell therapy is the transfer of cells with a desired biological function into a patient. The cells themselves are the medicine. Examples span a wide range:
- Stem cell transplants, such as bone marrow transplants used to rebuild a patient’s blood and immune system
- Immune cell infusions, where cells capable of fighting disease are delivered to the patient
- Tissue-based treatments, in which cells help repair or replace damaged tissue
Importantly, cell therapy does not necessarily involve altering anyone’s genetic material. Many cell therapies use cells in their natural state, relying on what those cells already do.
What Is Gene Therapy?
Gene therapy is the transfer of genetic material, delivered by a carrier known as a vector, so that targeted cells take up a new or corrected gene. The genetic instructions are the medicine.
Traditionally, gene therapy has focused on correcting or supplementing faulty genetic information. Viral vectors, which are modified viruses stripped of their ability to cause disease, have been the most common delivery vehicles. In its classic form, gene therapy was defined by the genetic payload rather than by any particular cell type.
Why They Were Historically Regulated and Studied as Different Categories
Because the underlying mechanisms differed, each field developed its own manufacturing standards, clinical endpoints, and regulatory pathways. A living cell product raises different questions than a genetic payload delivered by a vector. Regulators asked how cells were sourced, handled, and kept viable in one case, and how vectors were constructed, dosed, and tracked in the other.
For years, this separation made sense. In modern protocols, however, that clean boundary has increasingly broken down.
The Convergence Point: Ex Vivo Gene Editing of a Patient’s Own Cells
The central mechanism driving convergence is straightforward to describe. Many modern protocols now combine both approaches: a patient’s own stem cells or immune cells are isolated, genetically modified outside the body, expanded, and reinfused.
How the Combined Protocol Works, Step by Step
The general ex vivo (“outside the body”) workflow follows four stages:
- Cell collection. Cells are harvested from the patient, typically from blood or bone marrow.
- Genetic modification in culture. In a laboratory, the cells receive a new gene or a targeted edit, typically delivered via a viral vector or a gene-editing tool.
- Expansion. The modified cells are grown until they reach therapeutic numbers.
- Reinfusion. The finished cell product is returned to the patient.
This hybrid approach explains why a single product can legitimately be called both a “cell therapy” and a “gene therapy.” The label depends on which mechanism is being emphasized: the living cells doing the work, or the genetic change that equips them to do it.
CAR-T as the Clearest Real-World Example
CAR-T cell therapy is the textbook illustration of convergence. A patient’s T-cells, a type of immune cell, are collected and genetically modified in a lab to express a chimeric antigen receptor (CAR). This engineered receptor allows the T-cells to recognize and attack specific cancer cells. The modified cells are then infused back into the patient.
CAR-T embodies both definitions simultaneously. It is a transfer of cells with a desired function, and it is a transfer of genetic material into targeted cells. That dual identity sets up one of the most interesting regulatory questions in modern medicine, discussed below.
Casgevy and BCL11A Editing: Gene-Corrected HSC Therapy
Casgevy offers a second, distinct convergence archetype: gene-edited hematopoietic stem cell (HSC) therapy. In plain terms, the process works like this:
- Blood-producing CD34+ stem cells are extracted from the patient’s bone marrow.
- In the laboratory, these cells are edited using CRISPR to disrupt the BCL11A gene.
- The edited cells are reinfused into the patient, where they take up residence and produce new blood cells.
The downstream biology is what makes this approach elegant. BCL11A encodes a repressor that keeps the fetal (γ-globin) genes switched off in adulthood. Before birth, humans produce fetal hemoglobin; after birth, the body largely switches to adult hemoglobin. In sickle cell disease and beta thalassemia, adult hemoglobin is defective. By disrupting BCL11A, the edit reactivates fetal hemoglobin production, which compensates for the faulty adult version.
Casgevy broadens the convergence story beyond oncology. Hematopoietic stem and progenitor cell gene therapy, using lentiviral or gammaretroviral vectors, already has a clinical track record, and researchers are now exploring gene-edited HSCs for cancer as well, since they can provide a continuous, self-renewing source of therapeutic immune cells.
The Regulatory Classification Gap: US vs. EU
One of the least discussed aspects of cell gene therapy in consumer-facing explainers is how differently regions label the same products. This gap is a direct artifact of the fields’ separate origins.
EU ATMP Rules: CAR-T Is Legally a Gene Therapy
In the European Union, cell and gene products fall under the Advanced Therapy Medicinal Product (ATMP) framework. Under these rules, CAR-T therapies are typically classified legally as gene therapies. They are also sometimes described as cell-based gene therapies or as immunotherapies, since they modify the immune system to target disease.
The EU’s logic centers on the genetic modification step. Because the therapeutic effect depends on an introduced genetic sequence, that modification acts as the defining regulatory trigger.
US Framing: CAR-T Commonly Described as Cell Therapy
In the United States, the same class of products is frequently discussed publicly and clinically as “cell therapy.” Hospitals, patient resources, and media coverage often use that framing. At the same time, the FDA’s own list of approved cellular and gene therapy products groups both categories together under a single umbrella.
This is a difference in framing and communication, not in the underlying science or product. A CAR-T therapy infused in Boston works through the same mechanism as one infused in Berlin.
Why the Terminology Gap Matters for Patients and Industry
For companies, classification can influence:
- Clinical trial design, including which endpoints regulators expect
- Post-market surveillance requirements, such as long-term follow-up for genetic modifications
- Risk and benefit communication to regulators and patients across different regions
For general readers, the key reassurance is simple: the treatment and its mechanism are identical regardless of the label. The distinction is a regulatory and linguistic nuance, not a clinical one.
The 2026 Approval Landscape: What’s Actually on the Market
Many explainers still rely on a fixed set of older examples, such as Kymriah, Zolgensma, or Provenge. The 2026 landscape has moved well beyond that list.
Global Numbers: The Q1 2026 Landscape Report
According to the ASGCT/Citeline Gene, Cell, & RNA Therapy Landscape Report for Q1 2026, the global approved-therapy count stood at:
| Category | Approved Therapies (Global, Q1 2026) |
|---|---|
| Gene therapies (including genetically modified cell therapies) | 40 |
| RNA therapies | 37 |
| Non-genetically modified cell therapies | 75 |
These figures show the combined field’s scale. They also show that gene-modified cell therapies are now tracked as a distinct subcategory, grouped with gene therapies rather than with conventional cell therapies, which mirrors the convergence described above.
FDA’s Approved List and Its Growth
By August 2026, the FDA’s official list of approved cellular and gene therapy products reported 53 listed products, including cord-blood-defined therapies.
The growth trend has been building for several years. In 2024, the FDA approved 50 new drugs alongside nine new cellular and gene therapy products, for a total of 59 new medical therapies. That year continued a broader pattern: a greater share of first-in-class medicines, more fast-track approvals, and an expanding role for mRNA, gene, and cell-based therapies.
Otarmeni: The First OTOF Gene Therapy for Hearing Loss
In April 2026, Otarmeni (lunsotogene parvec, Regeneron)** became the first FDA-approved gene therapy for hearing loss caused by mutations in the OTOF gene. The therapy delivers durable improvements from a single dose.
Otarmeni matters beyond its own indication. It demonstrates that gene therapy is expanding well past oncology and blood disorders into sensory conditions, opening a new category of potential targets.
Tregzi (formerly Orca-T): Cell Therapy Supporting Transplant Outcomes
In June 2026, the FDA approved Tregzi (formerly Orca-T), a cell therapy used in allogeneic (donor-sourced) stem cell transplants for adults with hematological malignancies. Its goal is to improve survival free of chronic graft-versus-host disease (GVHD), a serious complication in which donor immune cells attack the recipient’s body.
Tregzi is a useful contrast. Unlike Casgevy and CAR-T, which are gene-modified cell therapies, Tregzi is a non-gene-modified cell therapy. Its approval shows that the field still contains both convergent and non-convergent products side by side.
Real-World Impact: Efficacy Versus Access
Approval is only the beginning. The more revealing questions concern how well these therapies work over time and how many patients can actually receive them.
Casgevy’s Two-Year Outcomes
- 94% remained completely free of pain crises
- Hemoglobin levels normalized
- Hospitalizations dropped 97%
These outcomes provide strong evidence that gene-edited cell therapy can function as a durable, potentially curative intervention for monogenic (single-gene) blood disorders.
The Access Gap: Treatment Capacity and Logistics
Despite this efficacy, only a small fraction of eligible patients have been treated so far. The constraint is not a lack of demand; it is limited manufacturing capacity and a limited number of qualified treatment centers.
The scale of the gap is sobering. Approximately 100,000 Americans live with sickle cell disease. At a treatment rate of roughly 525 patients per year, reaching every eligible American would take around 190 years. Capacity, not science, is the real bottleneck.
This access gap is not unique to one product. It is a recurring theme across autologous (patient-derived) gene-edited cell therapies generally, because each dose must be individually manufactured from a single patient’s cells.
What Treatment Actually Involves: Timeline and Intensity
The patient journey for an ex vivo gene-edited therapy like Casgevy typically spans 6 to 9 months and includes:
- Stem cell collection from the patient
- Several weeks of manufacturing at a centralized facility while the cells are edited
- Conditioning chemotherapy (busulfan) to clear space in the bone marrow for the edited cells
- Infusion of the modified cells
- 4 to 6 weeks of inpatient monitoring during engraftment, as the new cells establish themselves
This timeline helps explain why these therapies are logistically complex even when clinically effective. Each step requires specialized staff, facilities, and coordination, which constrains access independent of any other factor.
The Next Frontier: In Vivo CAR-T and the Literal Fusion of the Two Fields
Today’s landscape is dominated by ex vivo approaches. The next chapter of convergence aims to remove the laboratory step entirely.
Eliminating the Ex Vivo Step
In vivo (“inside the body”) CAR-T represents a fundamentally different architecture. Instead of extracting T-cells and engineering them in a lab, engineered vectors deliver CAR-encoding genetic material directly to T-cells inside the patient.
The implication is significant. The patient’s body becomes the site of cell-product generation, rather than the recipient of an externally manufactured product.
Why Researchers Call This the Literal Fusion of Both Fields
Peer-reviewed literature describes in vivo CAR engineering as the convergence of cell and gene therapy, establishing a conceptual foundation for programmable immunotherapy. A gene therapy delivery step directly produces a cell therapy outcome, with no separation between the two.
This matters for accessibility. ASGCT 2026 highlighted a definitive industry shift toward in vivo gene editing and AI-driven discovery, aimed at simplifying the therapeutic journey and broadening addressable patient populations by moving beyond complex, lab-based cell manipulation. In theory, removing the ex vivo manufacturing bottleneck could reach far more patients than current capacity allows.
Regulatory Ambiguity Ahead
Because in vivo CAR-T sits at the direct intersection of gene therapy and cell therapy, clear regulatory frameworks and appropriate evaluation endpoints are still being established.
This ambiguity continues the same definitional tension seen in the US/EU classification gap. The difference is that it is now playing out in real time for a next-generation modality that challenges both categories at once.
Manufacturing: The Bottleneck Tying Both Fields Together
Whatever a therapy is called, it must be produced at scale. Manufacturing is the industrial reality that constrains both cell and gene therapy.
Why Vector Supply Chains Matter
AAV and lentiviral vectors are essential to both ex vivo and in vivo approaches, and production capacity for them is concentrated among a relatively small number of specialized manufacturers, many based in the United States. This concentration creates a shared chokepoint.
It connects directly to the access discussion above: manufacturing capacity, not just the underlying science, determines how many patients can realistically be treated.
ASGCT 2026 Exhibitor Floor Snapshot
An analysis of the ASGCT 2026 exhibitor floor found a supply-chain-heavy event, with 37% of exhibitors operating in manufacturing and contract development and manufacturing organization (CDMO) services.
This snapshot suggests that the field’s biggest near-term challenge is industrial scale-up rather than further scientific proof-of-concept. The science has largely demonstrated what is possible; the industry is now focused on delivering it.
Making Sense of Market Size Estimates
Market figures for cell and gene therapy are widely repeated, often without context. A closer look reveals why readers should approach them carefully.
Divergent Estimates for the Combined Market
Two research firms offer notably different projections for the global cell and gene therapy market:
| Source Estimate | 2026 Value | 2035 Projection | CAGR |
|---|---|---|---|
| Estimate A (Global Market Insights) | USD 15.5 billion | USD 120.9 billion | 25.7% |
| Estimate B | USD 33.5 billion | ~USD 232.22 billion | 24% |
The starting values differ by more than double. This divergence typically stems from differing definitions of what counts as “cell and gene therapy,” such as whether RNA therapies, tools, or services are included, rather than disagreement about underlying demand.
CAR-T-Specific Forecasting Spread
The same pattern appears within CAR-T forecasts. One report places the 2026 CAR-T market at USD 16.23 billion, rising to USD 193.6 billion by 2035 at a 29.80% CAGR. A more conservative estimate puts 2026 at USD 3.45 billion, reaching USD 6.08 billion by 2030 at a 15.2% CAGR.
Readers should treat any single market-size figure as directional rather than definitive, and check a source’s methodology and scope before citing it.
Conclusion: One Convergence Point, Many Open Questions
Cell therapy and gene therapy began as distinct disciplines, each with its own regulatory logic. Ex vivo gene editing of a patient’s own cells is the mechanism that fused them, producing therapies like CAR-T and Casgevy that genuinely belong to both fields.
The US/EU classification gap remains a lingering artifact of that historical separation, and in vivo CAR-T is complicating matters further by blurring the line even more completely.
2026 stands out as a pivotal year. Otarmeni delivered a first for sensory disease, Tregzi showed that non-gene-modified cell therapy continues to advance, and Casgevy’s maturing data reinforced the curative potential of gene-edited cells. Yet the field’s defining constraints are now manufacturing capacity and access, not scientific feasibility.
Continue Exploring Cell and Gene Therapy
This primer is a starting point. Readers looking to build a deeper understanding can explore related foundational topics on adiamed.com, including how CRISPR editing works at the molecular level, detailed profiles of specific therapies such as Casgevy and individual CAR-T products, and analyses of the access challenges shaping who receives these treatments.
The field is moving quickly. With additional 2026 approvals expected and in vivo CAR-T programs advancing through clinical development, readers are encouraged to check back for ongoing coverage as this fast-moving landscape continues to evolve.
